Business Context and Reporting Period
Company: Predictive Oncology Inc. (POAI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: The Company applies AI to oncology drug discovery using a proprietary biobank of 150,000+ tumor samples and produces the FDA-cleared STREAMWAY System for medical fluid waste management. During Q3 2024, the Company discontinued its former Birmingham operating segment, resulting in two reportable segments: Pittsburgh (AI/Drug Discovery) and Eagan (STREAMWAY Systems).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $345,686 | $676,626 | $1,012,232 | $1,308,102 |
| Gross Profit | $148,767 | $578,758 | $476,721 | $940,641 |
| Gross Margin | 43% | 86% | 47% | 72% |
| Net Loss (Continuing Ops) | $(2,283,413) | $(2,748,367) | $(8,759,343) | $(9,025,398) |
| Net Loss (Total) | $(3,094,690) | $(3,163,450) | $(10,494,794) | $(10,508,620) |
| Cash & Equivalents | $3,078,955 | $11,915,048 | $3,078,955 | $11,915,048 |
| Operating Cash Flow (9M) | $(8,913,589) | $(9,060,285) | $(8,913,589) | $(9,060,285) |
| Current Liabilities | $3,816,766 | $3,951,031 | $3,816,766 | $3,951,031 |
Material Changes vs. Prior Period
- Discontinued Operations: The Birmingham operating segment was classified as discontinued operations in Q3 2024. This resulted in a loss from discontinued operations of $811,277 for Q3 2024 and $1,735,451 for the nine months ended September 30, 2024.
- Revenue Decline: Revenue decreased 49% in Q3 2024 and 23% in the nine-month period compared to 2023. This was driven by a significant drop in sales of high-margin 3D cell culture models (Pittsburgh segment), partially offset by increased sales of STREAMWAY systems (Eagan segment).
- Gross Margin Compression: Gross margins declined significantly (from 86% to 43% in Q3) due to the shift in sales mix toward lower-margin STREAMWAY products and increased labor costs.
- Expense Reduction: General and Administrative (G&A) expenses decreased by approximately 32% in Q3 2024 compared to the prior year, primarily due to reduced headcount and severance costs.
- Financing Activity: The Company raised approximately $3.7 million via an At-The-Market (ATM) offering in May 2024 and approximately $1.3 million via a warrant inducement transaction in July 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the Company's ability to continue as a going concern for one year from the filing date. The Company has an accumulated deficit of $178.3 million and requires significant additional capital to meet operating needs.
- Liquidity Position: As of September 30, 2024, cash and cash equivalents were $3.1 million. The Company does not expect to generate sufficient operating revenue to sustain operations in the near term.
- NASDAQ Compliance: The Company received notice of non-compliance with the Nasdaq minimum bid price requirement ($1.00) on September 19, 2024. It has until March 18, 2025, to regain compliance.
- Future Funding: The Company is evaluating alternatives including equity financing, debt issuance, or monetizing assets. Management warns that future financing may be highly dilutive or result in stockholders losing part or all of their investment.
- Segment Performance: The Pittsburgh segment (AI/Drug Discovery) continues to incur significant losses, while the Eagan segment (STREAMWAY) remains the primary revenue driver but with lower margins.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.1 million cash balance against the $3.8 million in current liabilities and ongoing burn rate.
- Financing Terms: Review the terms of any new equity or debt financing to assess potential dilution or restrictive covenants.
- NASDAQ Status: Monitor the Company's progress in regaining compliance with the minimum bid price requirement by March 2025.
- Discontinued Operations: Confirm the final settlement of liabilities and lease obligations related to the vacated Birmingham facility.
- Revenue Concentration: Note that a single customer represented 33% of revenue for the nine months ended September 30, 2024.